Docherty KF, Jhund PS, Claggett B, et al. - Addition of dapagliflozin to standard therapy for heart failure and reduced ejection fraction (HFrEF) affords clinically meaningful gains in extrapolated long-term, event-free, and overall survival.

• This is an exploratory analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure randomized clinical trial that included 4,744 patients with HFrEF who were randomized to dapagliflozin, 10 mg, once daily vs placebo in addition to standard therapy.

• Dapagliflozin provided longer extrapolated event-free and overall survival time than placebo.

• These results were generally consistent across the age range analyzed and in subgroups of patients in the trial.

• An event-free survival time gain of 2.1 years and a gain in survival of 1.7 years were conferred by dapagliflozin vs placebo.